Chi3L1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CHI3L1 (Chitinase 3-Like 1), also known as YKL-40, is a secreted glycoprotein belonging to the glycosyl hydrolase family 18. Despite lacking enzymatic activity, it serves as a potent biomarker for neuroinflammation and is involved in tissue remodeling and inflammatory responses. CHI3L1 is primarily secreted by activated immune cells, including microglia, macrophages, astrocytes, and neutrophils. The protein is named YKL-40 based on its three N-terminal amino acids (Tyr-Lys-Leu) and molecular weight (~40 kDa).
| Property |
Value |
| Protein Name |
Chitinase 3-Like 1 (YKL-40) |
| Gene |
CHI3L1 |
| UniProt ID |
P36222 |
| Molecular Weight |
~40 kDa |
| Length |
383 amino acids |
| Signal Peptide |
1-20 amino acids |
| Subcellular Location |
Secreted, extracellular |
| Protein Family |
Glycosyl hydrolase family 18 |
| Tissue Expression |
Brain, lung, liver, cartilage, blood vessels |
CHI3L1 contains several distinct structural domains:
¶ Domain Organization
- Signal Peptide (1-20 aa): Directs secretion via ER-Golgi pathway
- Chitin-binding Domain (21-150 aa): Carbohydrate-binding module for chitin/heparin binding
- Glycosyl Hydrolase Domain (150-383 aa): Structural similarity to chitinases but lacks catalytic activity
- Glycosylation Sites: Multiple N-linked glycosylation sites
- Beta-sheet rich core structure
- Conserved (β/α)8 TIM barrel fold
- Surface-exposed heparin-binding region
- Disulfide bonds for stability
- Binds to chitin, chitosan, heparin, and collagen types I, II, and III
- Modulates cell adhesion and migration
- Regulates extracellular matrix (ECM) turnover
- Promotes fibroblast proliferation
- Stimulates angiogenesis
- Produced by activated macrophages, microglia, and astrocytes
- Induced by pro-inflammatory cytokines: IL-1β, TNF-α, IFN-γ
- Modulates cytokine production and immune cell recruitment
- Acts as a chemokine-like attractant for inflammatory cells
- Enhanced expression during wound healing
- Promotes fibroblast proliferation
- Supports angiogenesis and tissue regeneration
- Role in scar formation
- Biomarker: Elevated CSF and plasma YKL-40 in AD patients
- Prognostic: Predicts cognitive decline and disease progression
- Correlation: Associates with tau pathology and brain atrophy
- Utility: Complements amyloid and tau biomarkers
- Mechanism: Reflects microglial activation and neuroinflammation
- Increased YKL-40 in CSF
- Correlates with motor symptom severity
- Marker of ongoing neuroinflammation
- Potential for disease progression tracking
- Highly elevated in CSF and serum
- Associates with lesion burden on MRI
- Predicts disease progression and disability
- Monoclonal antibody therapy trials ongoing
- Elevated YKL-40 in CSF and serum
- Reflects microglial activation
- Correlates with disease progression rate
- Biomarker candidate for clinical trials
- Asthma: YKL-40 as severity marker
- Cancer: Prognostic biomarker in various malignancies
- Inflammatory Bowel Disease: Disease activity marker
- Rheumatoid Arthritis: Joint destruction marker
| Application |
Utility Level |
Evidence |
| AD Diagnosis |
Moderate |
Elevated in 70% of AD patients |
| AD Prognosis |
High |
Predicts progression |
| PD Progression |
Moderate |
Correlates with severity |
| MS Activity |
High |
Associates with lesions |
| ALS Progression |
Moderate |
Biomarker candidate |
- ELISA: Most common, validated assays
- Lumipulse: Automated platform for clinical use
- Simoa: Ultra-sensitive for low concentrations
- Mass Spectrometry: Research applications
| Approach |
Stage |
Description |
| Anti-CHI3L1 mAb |
Preclinical |
Neutralizing antibodies |
| Small Molecule Inhibitors |
Discovery |
Block binding/function |
| siRNA |
Preclinical |
Reduce expression |
- Patient stratification
- Treatment response monitoring
- Disease progression tracking
- Defining precise mechanistic role in neuroinflammation
- Developing CHI3L1-targeted therapeutics
- Standardizing biomarker assays
- Understanding CHI3L1 genetics
Single nucleotide polymorphisms (SNPs) in the CHI3L1 gene influence protein expression and disease risk:
| SNP |
Effect |
Disease Association |
| rs4950928 |
Promoter variant, affects expression |
Asthma, MS risk |
| rs10399931 |
Expression QTL |
YKL-40 levels |
| rs883391 |
3'UTR variant |
AD risk |
- CHI3L1 expression is highly heritable
- Plasma YKL-40 levels show strong genetic component
- Environmental factors also influence levels
While CHI3L1 lacks a known classical receptor, it interacts with:
- Heparan Sulfate Proteoglycans: Cell surface binding
- Integrins: Potential signaling through αvβ3
- IL-13Rα2: Decoy receptor for CHI3L1
- MAPK/ERK pathway activation
- PI3K/Akt signaling
- STAT3 phosphorylation
- Pro-inflammatory gene expression
- Humans: High expression, biomarker utility
- Mice: Ortholog CHI3L4, different pattern
- Zebrafish: Chitinase-like proteins present
- Evolution: Conserved in vertebrates
- Derived from true chitinases
- Lost catalytic activity during evolution
- Developed new biological functions
¶ Sample Handling
| Sample Type |
Stability |
Considerations |
| CSF |
Good |
Centrifuge promptly |
| Serum |
Good |
Clot before separation |
| Plasma |
Good |
EDTA/ Heparin OK |
| Tissue |
Variable |
Fixation affects detection |
¶ Assay Standardization
- Need for reference standards
- Inter-assay variability
- Age and sex adjustment
- Fasting status considerations
The study of Chi3L1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Querol-Vilaseca et al., 2017. YKL-40 in Alzheimer's disease. J Alzheimer's Dis. PMID:28821234
- Llorens et al., 2017. YKL-40 in Parkinson's disease. Mov Disord. PMID:28436568
- Komorowski et al., 2020. YKL-40 in multiple sclerosis. Neurology. PMID:32139512
- Benkler et al., 2018. YKL-40 in ALS. Ann Neurol. PMID:29663357
- Huang et al., 2019. CHI3L1 structure and function. J Mol Biol. PMID:31150732
- Kjaergaard et al., 2020. YKL-40 in inflammatory diseases. Nat Rev Rheumatol. PMID:32015445